Floatz logo

Everolimus

Parkinson Disease (PD)

Royan InstituteSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Parkinson Disease (PD) cohort.

Asset / SponsorPhaseRating
18f-mfbg
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Phase 2CCC
Vgn-R08B
Shanghai Vitalgen BioPharma Co., Ltd.
Phase 1/2CC
18f-op-801
Ashvattha Therapeutics, Inc.
Phase 1/2CC
Dopacell
Royan Institute
Phase 1CC
Monomethyl Fumarate
Royan Institute
Phase 1CC

View all 9 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →